SCHEMBL17512431

SCHEMBL17512431

COc1ccc(C(=O)Nc2ccc(Cl)c(Cl)c2)cc1NC(=O)N(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.59
NPC1 O15118 8/20 0.57
RAB9A P51151 8/20 0.57
MAPT P10636 7/20 0.57
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
KDM4E B2RXH2 2/20 0.57
PKM P14618 1/20 0.57
MAPK14 Q16539 1/20 0.54
SMN1; SMN2 Q16637 8/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
TP53 P04637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 3/20 0.50
GLA P06280 1/20 0.50
MAOB P27338 2/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22966721 0.87 MAPT (0.61) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512417 0.87 NPC1 (0.61) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL19034468 0.87 NPC1 (0.61) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512380 0.85 NPC1 (0.53) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512421 0.85 HDAC8 (0.67) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512420 0.85 NPC1 (0.58) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512407 0.84 MAPT (0.57) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512423 0.83 RAB9A (0.56) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL19034493 0.83 NPC1 (0.56) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL17512375 0.83 KDM4E (0.69) NPC1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
WO-2016029136-A1 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G NORTHWESTERN UNIVERSITY (US) 2016-02-25 WO disclosed
US-20160052870-A1 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS NORTHWESTERN UNIVERSITY (US) 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052870-A1 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS L3MBTL3, AFG3L2, AMPD3 APEX1 1513/4885NPC1 2573/4885RAB9A 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.